Lecture series Infection & Immunity: "TREATING INFLAMMATION WITH IL-1 BLOCKADE FROM GOUT TO CANCER" - Prof Charles Dinarello
21/03/2019 09:00 to 21/03/2019 12:00 (Europe/Luxembourg)
Interleukin-1 (IL-1α and IL-1ß) are highly active proinflammatory cytokines. Three IL-1-targeted agents have been approved: the IL-1 receptor antagonist (anakinra), a soluble decoy receptor (rilonacept), and a neutralizing monoclonal anti-interleukin-1ß antibody (canakinumab). In addition, a monoclonal antibody directed against IL-1α is in clinical trials in cancer. Monotherapy blocking IL-1ß IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity. A world-wide randomized placebo controlled trial in over 10,000 subjects of canakinumab revealed the pivotal role of IL-1ß in atherosclerosis, heart failure, gout, osteoarthritis and lung cancer. A randomized placebo controlled trial of anti-IL-1α revealed the role of IL-1α in cancer cachexia.
09:00 - 10:00 : LECTURE
Lycée Guillaume Kroll Salle de projection audiovisuelle
10:30 - 12:00 : 'meet & eat'
House of BioHealth
Room Françoise Barré-Sinoussi
Registration required for the 'Meet & Eat' - send us an email.
About the Lecture & Workshop series - Infection & Immunity
The LIH Lecture Series and Workshops in Infection and Immunity, supported by the FNR, are gathering internationally recognised speakers to address topics around Infection and Immunity. Twelve lectures will be organised in 2019, followed by workshops especially dedicated to early-stage researchers. Please find here the full programme for 2019.
Attendance to the lectures and workshops are free of charge. Should you be interested in registering for the workshops, please feel free to do so by sending us an email.